Humira 2023 global sales 14.4 billion?

Q: Humira 2023 global sales 14.4 billion?

Yes – AbbVie’s financial statements confirm that Humira generated roughly $14.4 billion in global sales in 2023 . Year Total Global Sales (USD) Notes 2022 ~ $15.0 B (≈ $15 billion) Humira was the world’s top‑selling drug. 2023 $14.4 B Slight decline due to intensified competition from multiple biosimilar launches (e.g., Samsung Biologics, Sandoz, Amgen, etc.) and market‑share erosion in the U.S. and EU. Key points to keep in mind AbbVie’s reporting – The $14.4 B figure comes from AbbVie’s 2023 annual report (FY 2023) and reflects net sales across all markets where Humira is sold. Biosimilar impact – 2023 was a watershed year: the first commercial launch of a Humira biosimilar (e.g., “Adalimumab” biosimilars) in the U.S. and Europe has begun to erode Humira’s share. Comparisons – While a drop from the previous year, Humira still remains one of the highest‑selling biologics worldwide, accounting for about 5 % of AbbVie’s overall net sales in 2023. If you need more detailed breakdowns (regional sales, pricing trends, or a comparison with the biosimilar competitors), feel free to let me know!

Question

Accepted Answer

Yes – AbbVie’s financial statements confirm that Humira generated roughly $14.4 billion in global sales in 2023.

Year	Total Global Sales (USD)	Notes
2022	~ $15.0 B (≈ $15 billion)	Humira was the world’s top‑selling drug.
2023	$14.4 B	Slight decline due to intensified competition from multiple biosimilar launches (e.g., Samsung Biologics, Sandoz, Amgen, etc.) and market‑share erosion in the U.S. and EU.

Key points to keep in mind

AbbVie’s reporting – The $14.4 B figure comes from AbbVie’s 2023 annual report (FY 2023) and reflects net sales across all markets where Humira is sold.
Biosimilar impact – 2023 was a watershed year: the first commercial launch of a Humira biosimilar (e.g., “Adalimumab” biosimilars) in the U.S. and Europe has begun to erode Humira’s share.
Comparisons – While a drop from the previous year, Humira still remains one of the highest‑selling biologics worldwide, accounting for about 5 % of AbbVie’s overall net sales in 2023.

If you need more detailed breakdowns (regional sales, pricing trends, or a comparison with the biosimilar competitors), feel free to let me know!

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Humira 2023 global sales 14.4 billion?